Versigent reported a strong first full quarter as an independent company, with sales increasing by 10.8% and adjusted EBITDA rising 24.8%. Despite the stock being less cheap than right after its separation from Aptiv, its valuation at about 5.1 times expected 2026 adjusted EBITDA is still considered reasonable. Key concerns include the company's debt levels and weak cash conversion in the first half of the year. The analyst rates Versigent as a Buy, valuing shares at $58, approximately 24% above the current market price, indicating potential upside for investors.
Injective's institutional services arm has become the first Layer 1 blockchain registered as a transfer agent with the SEC, enabling regulated recordkeeping for tokenized securities. This status supports four live asset classes including public equit...
Meta Platforms is deploying a new technology called CXL to recycle older DDR4 memory modules in newer DDR5 servers. This approach helps Meta manage rising DRAM prices and reduces the total cost of ownership for its server hardware. By creatively reus...
Dynatrace is successfully transitioning from an observability tool to a full AI operations platform, maintaining 16% ARR growth and high profitability with mid-80% gross margins. The company focuses on sustainable growth and disciplined execution rat...
Bitcoin surged above $75,000, marking a 20% gain over four days and reaching its highest level since late May. This rally outpaced Ethereum and Solana, driven by a strong reaction from key support levels and significant short squeezes that liquidated...
Lattice Semiconductor has shown strong recovery from the recent semiconductor downturn, with Q2 revenue rising 62% year-over-year. The company exceeded expectations with a gross margin of 71.7% and an operating margin of 38.3%. Its acquisition of AMI...
